Unknown

Dataset Information

0

K-Ras and ?-catenin mutations cooperate with Fgfr3 mutations in mice to promote tumorigenesis in the skin and lung, but not in the bladder.


ABSTRACT: The human fibroblast growth factor receptor 3 (FGFR3) gene is frequently mutated in superficial urothelial cell carcinoma (UCC). To test the functional significance of FGFR3 activating mutations as a 'driver' of UCC, we targeted the expression of mutated Fgfr3 to the murine urothelium using Cre-loxP recombination driven by the uroplakin II promoter. The introduction of the Fgfr3 mutations resulted in no obvious effect on tumorigenesis up to 18 months of age. Furthermore, even when the Fgfr3 mutations were introduced together with K-Ras or ?-catenin (Ctnnb1) activating mutations, no urothelial dysplasia or UCC was observed. Interestingly, however, owing to a sporadic ectopic Cre recombinase expression in the skin and lung of these mice, Fgfr3 mutation caused papilloma and promoted lung tumorigenesis in cooperation with K-Ras and ?-catenin activation, respectively. These results indicate that activation of FGFR3 can cooperate with other mutations to drive tumorigenesis in a context-dependent manner, and support the hypothesis that activation of FGFR3 signaling contributes to human cancer.

SUBMITTER: Ahmad I 

PROVIDER: S-EPMC3124065 | biostudies-literature | 2011 Jul

REPOSITORIES: biostudies-literature

altmetric image

Publications

K-Ras and β-catenin mutations cooperate with Fgfr3 mutations in mice to promote tumorigenesis in the skin and lung, but not in the bladder.

Ahmad Imran I   Singh Lukram Babloo LB   Foth Mona M   Morris Carol-Ann CA   Taketo Makoto Mark MM   Wu Xue-Ru XR   Leung Hing Y HY   Sansom Owen J OJ   Iwata Tomoko T  

Disease models & mechanisms 20110418 4


The human fibroblast growth factor receptor 3 (FGFR3) gene is frequently mutated in superficial urothelial cell carcinoma (UCC). To test the functional significance of FGFR3 activating mutations as a 'driver' of UCC, we targeted the expression of mutated Fgfr3 to the murine urothelium using Cre-loxP recombination driven by the uroplakin II promoter. The introduction of the Fgfr3 mutations resulted in no obvious effect on tumorigenesis up to 18 months of age. Furthermore, even when the Fgfr3 muta  ...[more]

Similar Datasets

| S-EPMC2719950 | biostudies-literature
| S-EPMC6373451 | biostudies-literature
| S-EPMC5391708 | biostudies-literature
| S-EPMC3874239 | biostudies-literature
2019-01-28 | GSE113695 | GEO
| S-EPMC7610658 | biostudies-literature
| S-EPMC4134691 | biostudies-literature
| S-EPMC3101820 | biostudies-other
| S-EPMC10044160 | biostudies-literature
| S-EPMC6128396 | biostudies-literature